^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Pozenveo (poziotinib) (HER2 inhibitor, HER4 inhibitor, pan-EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

    Excerpt:
    ...Patients with EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q, etc) known to be associated with sensitivity to TKIs 2....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

    Excerpt:
    ...- Cohort 6: Patients with EGFR mutation-positive NSCLC who progressed while on treatment with first-line osimertinib...
    Trial ID:
    ZENITH20
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P76.86 - Poziotinib for EGFR and HER2 Exon 20 Insertion Mutation in Advanced NSCLC: Results from the Expanded Access Program.

    Published date:
    01/12/2021
    Excerpt:
    Poziotinib demonstrated clinical activity in mNSCLC patients with EGFR/HER2-exon 20-i-mut…